Suanfarma Suanfarma

X

Find the latest Drugs in Development and Pipeline Prospector News of Oncomatryx.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Oncomatryx
Spain_new Flag
Country
Country
Spain
Address
Address
Parque Tecnológico de Bizkaia 801B – 2P 48160 Derio. Bizkaia
Telephone
Telephone
+34 946 087 037
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Through the acquisition, Oncomatryx will foster its leadership in ADCs targeting the tumor microenvironment. Oncomatryx's pioneering drug OMTX705, which incorporates the cytolysin toxic payload developed by Tube, is a first-in-class ADC targeting cancer-associated fibroblasts.


Lead Product(s): OMTX705,Pembrolizumab

Therapeutic Area: Oncology Product Name: OMTX705

Highest Development Status: Phase IProduct Type: Large molecule

Recipient: Tubepharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition May 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, the Cancer-Associated Fibroblasts that enable tumor metastasis, drug resistance and immunosuppression.


Lead Product(s): OMTX705

Therapeutic Area: Oncology Product Name: OMTX705

Highest Development Status: IND EnablingProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 31, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

These funds, together with Oncomatryx recurring revenues from its licensing agreements with international biopharmaceutical companies, will be used for the clinical development of additional ADCs of Oncomatryx tumour-microenvironment pipeline including OMTX705.


Lead Product(s): OMTX705

Therapeutic Area: Oncology Product Name: OMTX705

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $16.0 million Upfront Cash: Undisclosed

Deal Type: Financing April 22, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY